Statin-induced myopathy: the two faces of Janus (Q34554637)

3 August 2017

1 reference

title

Statin-induced myopathy: the two faces of Janus (English)

1 reference

3 August 2017

Rohit Arora

1

1 reference

3 August 2017

Max Liebo

series ordinal

2

1 reference

3 August 2017

Frank Maldonado

series ordinal

3

1 reference

3 August 2017

1 June 2006

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

3 August 2017

1 reference

3 August 2017

11

1 reference

3 August 2017

2

1 reference

3 August 2017

105-112

1 reference

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

3 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Current overview of statin-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

A general assessment of the safety of HMG CoA reductase inhibitors (statins).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

HMG-CoA reductase inhibitors and myotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Statin-associated myopathy with normal creatine kinase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

FDA adverse event reports on statin-associated rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Cerivastatin and reports of fatal rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis".

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Comparative pharmacology of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Rosuvastatin for the treatment of patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

21 January 2018

Safety of rosuvastatin

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

21 January 2018

Statins and myotoxicity

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

The myotoxicity of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Rhabdomyolysis and HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

Safety of statins: focus on clinical pharmacokinetics and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248406288758

21 January 2018

Identifiers

DOI

10.1177/1074248406288758

0 references

1 reference